Giant cell arteritis. Part II. Treatment
https://doi.org/10.14412/1996-7012-2012-762
Abstract
Treatment options for giant cell arteritis (GCA) and its complications are considered. GCA is treatable with glucocorticoids (GC). The data available in the literature suggest that it is necessary to hospitalize GCA patients with acute vision loss or brain ischemia to administer intravenous megadose methylprednisolone and to control and prevent complications of GC therapy. It is expedient to use aspirin in these cases. The evidence for the use of methotrexate and other disease-modifying antirheumatic and genetically engineered drugs as GC-saving drugs is discussed.
References
1. <div><p>Fraser J.A., Weyand C.M., Newman N.J. et al. The Treatment of Giant Cell Arteritis. Rev Neurol Dis 2008; 5(3): 140—52.</p><p>Salvarani C., Cantini F., Bolardi L. et al. Polymyalgia rheumatica and giant-cell arteritis. N Engl J Med 2002; 347: 261 —71.</p><p>Rahman W., Rahman F.Z. Major review Р giant cell (temporal) arteritis: an overview and update. Surv Ophthalmol 2005; 50: 415—28.</p><p>Hayreh S.S., Zimmerman В. Management of giant cell arteritis. Our 27-year clinical study: new light on old controversies. Ophthalmologica 2003; 217: 239—59.</p><p>Pipitone N., Boiardi L., Salvarini C. Are steroids alone sufficient for the treatment of giant cell arteritis? Best Pract Res Clin Rheum 2005; 19: 277—92.</p><p>Lundberg I., Hedfors E. Restricted dose and duration of corticosteroid treatment in patients with polymyalgia rheumatic and temporal arteritis. J Rheum 1990; 17: 1340—5.</p><p>Weyand C.M., Goronzy J.J. Medium- and large-vessel vasculitis. N Engl J Med 2003; 349: 160—9.</p><p>Chevalet P., Barrier J.H., Pottier P. et al. A randomized, multicenter, controlled trial using intravenous pulses of methylprednisolone in the initial treatment of simple forms of giant cell arteritis: a one year follow-up study of 164 patients. J Rheum 2000; 27: 1484—91.</p><p>Mazlumzadeh M., Hunder G.G., Easley K.A. et al. Treatment of giant cell arteritis using induction therapy with highdose corticosteroids: a double-blind, placebocontrolled, randomized prospective clinical trial. Arthr Rheum 2006; 54: 3310—8.</p><p>Chan C.C.K., Paine M., O’Day J. Steroid management in giant cell arteritis. Br J Ophthalmol 2001; 85: 1061—4.</p><p>Hayreh S.S., Zimmerman В., Kardon R.H. Visual improvement with corticosteroid therapy in giant cell arteritis: report of a large study and review of the literature. Acta Ophthalmol Scand 2002; 80: 353—67.</p><p>Foroozan R., Deramo V.A., Buono L.M. et al. Recovery of visual function in patients with biopsy-proven giant cell arteritis. Ophthalmology 2003; 110: 539—42.</p><p>Danesh-Meyer H., Savino P.J., Gamble G.G. Poor prognosis of visual outcome after visual loss from giant cell arteritis. Ophthalmology 2005; 112: 1098—103.</p><p>Eberhardt R.T., Dhadly M. Giant cell arteritis: diagnosis, management, and cardiovascular implications. Cardiol Rev 2007; 15: 55—61.</p><p>Cornblath W.T., Eggenberger E.R. Progressive visual loss from giant cell arteritis despite high-dose intravenous methylprednisolone. Ophthalmology 1997; 104: 854—8.</p><p>Loddenkemper T., Sharma P., Katzan I. et al. Risk factors for early visual deterioration in temporal arteritis. J Neurol Neurosurg Psychiatry 2007; 78: 1255—9.</p><p>Gonzales-Gay M.A., Blanco R., Rodriguez-Valverde V. et al. Permanent visual loss and cerebrovascular accidents in giant cell arteritis: predictors and response to treatment. Arthr Rheum1998; 41: 1497—504.</p><p>Hayreh S.S., Zimmerman B. Visual deterioration in giant cell arteritis patients while on high doses of corticosteroid therapy. Ophthalmology 2003; 110: 1204—15.</p><p>Rucker J.C., Biousse V., Newman N.J. Ischemic optic neuropathies. Curr Opin Neurol 2004; 17: 27—35.</p><p>Hunder G.G., Sheps S.G., Allen G.L. et al. Daily and alternate-day corticosteroid regimens in treatment of giant cell arteritis: comparison in a prospective study. Ann Int Med 1975; 82: 613—8.</p><p>Weyand C.M., Fulbright J.W., Hunder G.G. et al. Treatment of giant cell arteritis: Interleukin-6 as a biologic marker of disease activity. Arthr Rheum 2000; 43: 1041—8.</p><p>Wilke W.S., Hoffman G.S. Treatment of corticosteroid-resistant giant cell arteritis. Rheum Dis Clin North Am 1995; 21: 59—71.</p><p>Spiera R.F., Mitnick H.J., Kupersmith M. et al. A prospective, double-blind, randomized, placebo controlled trial of methotrexate in the treatment of giant cell arteritis (GCA). Clin Exp Rheum 2001; 19: 495—501.</p><p>Hoffman G.S., Cid M.C., Hellmann D.B. et al. for the International Network for the Study of Systemic Vasculitides (INSSYS) A multicenter, randomized, double-blind, placebo-controlled trial of adjuvant methotrexate treatment for giant cell arteritis. Arthr Rheum 2002; 46: 1309—18.</p><p>Jover J.A., Hernandez-Garcia C., Morado I.C. et al. Combined treatment of giant-cell arteritis with methotrexate and prednisone: a randomized, double-blind, placebo-controlled trial. Ann Int Med 2001; 134: 106—14.</p><p>Mahr A.D., Jover J.A., Spiera R.D. et al. Adjunctive methotrexate for treatment of giant cell arteritis: an individual patient data meta-analysis. Arthr Rheum 2007; 56: 2789—97.</p><p>Hoffman G.S., Cid M.C., Rendt-Zagar K.E. et al. Infliximab for maintenance of glucocorticoid-induced remission of giant cell arteritis. Ann Int Med 2007; 146: 621 —30.</p><p>Martinez-Taboada V.M., Rodriguez-Valverde V., Carreno L. et al. A double-blind placebo controlled trial of etanercept in patients with giant cell arteritis and corticosteroid side effects. Ann Rheum Dis 2008; 67: 625—30.</p><p>De Silva M., Hazleman B.L. Azathioprine in giant cell arteritis/polymyalgia rheumatica: a double-blind study. Ann Rheum Dis 1986; 45: 136—8.</p><p>Schaufelberger C., Hollby H., Bratt J. et al. No additional steroid-sparing effect of cyclosporine A in giant cell arteritis. Scand J Rheum 2006; 35: 327—9.</p><p>Field M., Cook A., Gallagher G. Immunolocalisation of tumour necrosis factor and its receptors in temporal arteritis. Rheum Int 1997; 17: 113—8.</p><p>Cantini F., Niccoli L., Savarani C. et al. Treatment of longstanding active giant cell arteritis with infliximab: report of four cases. Arthr Rheum 2001; 44: 2933—5.</p><p>Uthman I., Kanj N., Atweh S. Infliximab as monotherapy in giant cell arteritis. Clin Rheum 2006; 25: 109—10.</p><p>Nuenninghoff D.M., Matteson E.L. The role of disease-modifying antirheumatic drugs in the treatment of giant cell arteritis. Clin Exp Rheum 2003; 21(6 Suppl 2): S29—34.</p><p>Liozon F., Vidal E., Barrier J. Does dapsone have a role in the treatment of temporal arteritis with regard to efficacy and toxicity? Clin Exp Rheum 1993; 11: 694—5.</p><p>Nesher G., Sonnenblick M. Steroid-sparing medications in temporal arteritis: report of three cases and review of 174 reported patients. Clin Rheum 1994; 13: 289—92.</p><p>Doury P., Pattin S., Eulry F. et al. The use of dapsone in the treatment of giant cell arteritis and polymyalgia rheumatica. Arthr Rheum 1983; 26: 689—90.</p><p>De Vita S., Tavoni A., Jeracitano G. et al. Treatment of giant cell arteritis with cyclophosphamide pulses. J Int Med 1992; 232: 373—5.</p><p>Ahmed M.M., Mubashir E., Hayat S. et al. Treatment of refractory temporal arteritis with adalimumab. Clin Rheum 2007; 26: 1353—5.</p><p>Leydet-Quilici H., Luc M., Armingeat T. et al. Giant cell arteritis during adalimumab treatment for rheumatoid arthritis. J Bone Spine 2007; 74: 299—305.</p><p>Bhatia A., Ell P.J., Edwards J.C.W. Anti-CD20 monoclonal antibody (rituximab) as an adjunct in the treatment of giant cell arteritis. Ann Rheum Dis 2005; 64: 1099—100.</p><p>Mukhtyar C., Guilevin L., Cid M.C. et al. EULAR recommendations for the management of large vessel vasculitis. Ann Rheum Dis 2009; 3: 318—23.</p><p>Баранов А.А. Рекомендации по ведению больных васкулитами (по материалам рекомендаций европейской антиревматической лиги). Совр. ревматол. 2009; 2: 5-9.</p><p>Национальное руководство по ревматологии. Под ред. Е.Л. Насонова, В.А. Насоновой. М.: ГЭОТАР-Медиа, 2008; 565—7.</p><p>Seitz M., Reichenbach S., Bonel H.M. et al. Rapid induction of remission in large vessel vasculitis by IL-6 blockade. A case series. Swiss Med Wkly 2011; 141: w13156.</p><p>Vinit J., Bielefeld P., Muller G. et al. Efficacy of tocilizumab in refractory giant cell arteritis. J Bone Spine 2012 [Epub ahead of print].</p><p>Catanoso M., Pipitone N., Magnani L. et al. New indications for biological therapies. Int Emerg Med 2011; 6(Suppl 1): 1—9.</p></div><br />
Review
For citations:
Satybaldyev AM. Giant cell arteritis. Part II. Treatment. Sovremennaya Revmatologiya=Modern Rheumatology Journal. 2012;6(4):49-54. (In Russ.) https://doi.org/10.14412/1996-7012-2012-762
Views:
1349
Email this article 